Cionic

CIONIC operates at the intersection of medical devices, neurotechnology, rehabilitation, and digital health. Its differentiation is the integration of a wearable sleeve, electrical stimulation, motion sensing, an app, and specialist-supported care into one mobility platform. The company says its system addresses more than 20 neurological conditions, including multiple sclerosis, cerebral palsy, stroke, and spinal cord injury, while its reported scale includes 2 million hours of real-world wear, 500 million stimulated steps, and 1,500 prescribers. Neural Sleeve 2 adds simultaneous muscle activation and spasm relaxation through AI-driven MultiStim, extending beyond simpler assistive or monitoring wearables. CIONIC also cites partnerships with clinical and research organizations such as Shirley Ryan AbilityLab and Stanford University, supporting a clinically oriented model. Relative to conventional orthotics or single-purpose functional electrical stimulation devices, CIONIC’s stated advantage is the combination of adaptive stimulation, gait retraining, progress tracking, and ongoing care services. Its principal market challenge is converting regulatory clearance and clinical interest into broad reimbursement and sustained patient adoption.

CIONIC’s trajectory shows a progression from early-stage neurotechnology development to a more complete mobility-care platform. The company was founded in 2018 and raised $3 million in August 2018, followed by $7.75 million in April 2020. It added a $12.5 million Series A in September 2022 and a further $12 million Series A in October 2023, bringing total disclosed funding to $35.25 million across five rounds. Product development then advanced from the original Neural Sleeve to Neural Sleeve 2, which received FDA clearance and launched in the United States on September 23, 2025. The newer device adds spasm-relaxation capabilities and AI-driven MultiStim, creating a broader clinical use case. In parallel, CIONIC expanded its software and service layer through the Cionic App, Mobility Specialists, training programs, and a care plan. Three East Coast Centers of Excellence announced in 2024 provide evidence of an effort to expand clinical access. The company’s 2026 innovation recognition and 2026 real-world evidence work suggest increasing emphasis on validation and market credibility.